Journal article

2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.

  • Zimmerman S Oncology Department, Service of Immuno-Oncology, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: Stefan.Zimmerman@chuv.ch.
  • Das A New York University Langone Health, New York, New York.
  • Wang S Peking University Cancer Hospital, Beijing, People's Republic of China.
  • Julian R New York University Langone Health, New York, New York; Laura and Isaac Perlmutter Cancer Center, New York, New York; New York University School of Medicine, New York, New York.
  • Gandhi L New York University Langone Health, New York, New York; Laura and Isaac Perlmutter Cancer Center, New York, New York; New York University School of Medicine, New York, New York.
  • Wolf J Center for Integrated Oncology Köln Bonn, University Clinic Köln, Köln, Germany.
Show more…
  • 2019-02-15
Published in:
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. - 2019
English SCLC remains an aggressive, deadly cancer with only modest effect on survival from standard chemotherapy. However, with the advent of immunotherapy and comprehensive genomic and transcriptomic profiling, multiple new targets are showing promise in the clinical arena, and just recently programmed death ligand 1 inhibition has been shown to improve the efficacy of standard chemotherapy in extended-disease SCLC. Our increasing understanding of the interactions between different pathways will enable more tailored immunotherapy and targeted therapies based on specific biomarkers and rational combinations. Here we discuss the preclinical and clinical strides in 2017 and 2018 that put us on the threshold of a new era in therapeutics and will, it is hoped, translate into significant improvements in survival.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/115525
Statistics

Document views: 10 File downloads:
  • fulltext.pdf: 0